جستجوی استاد راهنمای دانشگاهی

Dr. Irene Nobeli is a Senior Lecturer and Education Lead (PG taught courses) at the School of Natural Sciences, Birkbeck, University of London. She specializes in computational biology and chemoinformatics, focusing on regulatory RNAs, transcriptomics in health/disease, brain disorders, and small molecule roles in biology. Her work bridges bioinformatics tools development and translational research. Administrative roles include directing the MSc Bioinformatics program and organizing the Sequence Analysis and Omics module. She collaborates with research centers like the Birkbeck Institute for Data Analytics (BIDA) and the Institute of Structural Molecular Biology (ISMB). Research interests span bioinformatics methodologies, Mycobacterium genomics, neurodevelopmental disorders, and computational drug design. Notable contributions include developing flexiMAP (alternative polyadenylation analysis) and baerhunter (bacterial non-coding RNA detection). Publications highlight her expertise in transcriptomics, bacterial pathogenesis, and neurobiological mechanisms. She actively engages in advancing computational methods for genomic data interpretation and translational medicine.

• Bioinformatics
• Transcriptomics
• Regulatory RNAs
• +۳ مورد دیگر

Professor Ronald van Rij holds the position of Professor of Experimental Virology and Head of the Laboratory of Experimental Virology at Radboud University Medical Center in Nijmegen, Netherlands. He also serves as a Guest Professor at the University of Pavia, Italy. His research focuses on antiviral mechanisms in insects, particularly the roles of RNA interference (RNAi) and piRNA pathways in Drosophila melanogaster and Aedes aegypti mosquitoes. He has pioneered studies on viral defense in insects and vector competence, with translational work on antiviral compounds against pathogens like Zika and SARS-CoV-2 through the international 'COVID Moonshot' project. Education includes a PhD from the University of Amsterdam (2002) and postdoctoral fellowships at UCSF (USA) and the Hubrecht Institute (Netherlands). He has received prestigious grants such as ERC Consolidator and VICI awards, and was honored as Lecturer of the Year (2019) and PhD Supervisor of the Year (2017). Awards: ERC Proof of Concept Grant (2020), NWO VICI (2017), ERC Consolidator (2014), NWO VIDI (2008), EMBO Fellowship (2002). Teaching: Coordinates courses on virology, non-coding RNA, and innate immunity at Radboud University. Labs: Manages a BSL-3 facility for studying vector-borne pathogens in mosquitoes. His work bridges basic science and translational medicine, with emphasis on small RNA pathways and arbovirus control.

• Antiviral research
• piRNA pathway
• Insect viruses
• +۷ مورد دیگر

Julie Ahringer is Professor of Genetics and Genomics at the University of Cambridge and Director of the Wellcome Trust/Cancer Research UK Gurdon Institute. She leads a research group investigating chromatin structure and gene regulation using C. elegans as a model system. Her work integrates genomics, super-resolution microscopy, and computational approaches to understand epigenetic controls in development and disease. She holds fellowships from the Royal Society (FRS) and Academy of Medical Sciences (FMedSci). Research Focus: Her laboratory studies chromatin regulation mechanisms including heterochromatin formation, Polycomb domain function, genome architecture, and enhancer/promoter interactions. Key approaches include single-cell multiomics, high-throughput genomics, and super-resolution microscopy to analyze developmental trajectories. Research areas span: H3K27me3 domain formation and Polycomb repression Constitutive heterochromatin organization Regulatory element characterization 3D genome architecture via ARC-C technology Single-cell resolution developmental mapping Awards & Honors: Fellow of the Royal Society (FRS) Fellow of the Academy of Medical Sciences (FMedSci) Wellcome Senior Research Fellowship Academic Leadership: She mentors PhD students and postdoctoral researchers, with funding from Wellcome, MRC, and CRUK. Her lab develops open-source bioinformatics tools (VplotR, periodicDNA) and maintains the genome-wide C. elegans RNAi feeding library. Lab & Collaborations: The Ahringer Lab is based at the Gurdon Institute and collaborates widely on chromatin dynamics, nuclear organization, and developmental genomics projects across model organisms.

• Chromatin Regulation
• Epigenetics
• Genome Organization
• +۳ مورد دیگر

Wendy P. Robinson is a Professor in the Department of Medical Genetics at the University of British Columbia Faculty of Medicine , and a Senior Scientist at the BC Children’s Hospital Research Institute . She holds the CIHR Sex and Gender Science Chair . Research Interests: Genetics and epigenetics of early human development, placental function in pregnancy complications (fetal growth restriction, preterm birth), DNA methylation, non-coding RNA, sex differences, and polymorphisms. Her lab employs genomic and bioinformatic tools to study placental health and its impact on newborn outcomes. Recent Publications (2025-2024) focus on X-chromosome inactivation patterns in placenta, cell-type specific DNA methylation, maternal socioeconomic effects on placental epigenetics, and modeling placental development with organoids. Key themes include sex-specific epigenetic regulation , maternal-fetal interactions , and human placental methylome . Awards: UBC Faculty of Medicine Distinguished Achievement Award (2018), with trainees receiving the James Miller Memorial Prize and Mary-Jane Carroll Trainee Award. Students & Collaborations: Supervised PhD/MSc students include Li Qing Wang, Icíar Fernández Boyano, Giulia Del Gobbo, Victor Yuan, and Magda Price. Collaborators span the Alex Beristain Lab and University of Toronto institutions. Laboratory Activities: Regular team-building events like mountain hikes, climbing outings, and kayaking trips, alongside providing open access to epigenetic tools (e.g., Bisearch, SeqDoc) for the research community.

• Medical Genetics
• Epigenetics
• Fetal Development
• +۴ مورد دیگر

Demian Cazalla is an Associate Professor in the Department of Biochemistry at the University of Utah, focusing on the functional roles of non-coding RNAs (ncRNAs) in gene expression regulation. He is affiliated with the Molecular Biology Program and Biological Chemistry Program, contributing to interdisciplinary research in RNA biology. Education: M.Sc., University of Buenos Aires, Argentina Ph.D., Open University/MRC Human Genetics Unit, Edinburgh, Scotland Dr. Cazalla's research investigates how ncRNAs, particularly those expressed by oncogenic herpesviruses like Herpesvirus saimiri (HVS), regulate gene expression. His lab explores the structural and molecular mechanisms of viral ncRNAs (HSURs), their interactions with host miRNAs, and their role in viral oncogenesis through miRNA degradation and mRNA targeting. Current projects involve biochemical analysis of RNA-protein complexes and high-throughput sequencing to identify RNA targets. His recent publications highlight viral miRNA biogenesis pathways, ncRNA structural dynamics, and RNA-based regulatory networks. The work spans molecular virology, RNA biochemistry, and gene expression control in complex organisms.

• Non-coding RNA biology
• Gene expression regulation
• Viral oncogenesis
• +۳ مورد دیگر

Lill-Tove Rasmussen Busund is a Professor and Consultant Pathologist at the Department of Medical Biology, UiT The Arctic University of Norway. Her research focuses on translational cancer studies with emphasis on cancer biomarkers in tissue and blood, combining molecular biology with artificial intelligence applications in pathology. She leads the Translational Cancer Research Group (TCRG) and contributes to projects like the TNM-Immune Cell Score Trial and AI–Pathology initiatives. Role: Professor/Consultant Pathologist University: UiT The Arctic University of Norway Department: Department of Medical Biology Email: lill.tove.rasmussen.busund@uit.no Rasmussen Busund's work spans epidemiological cancer research , multi-omic data integration , and machine learning applications for cancer diagnostics. She develops prognostic and predictive biomarkers using population-based cohorts like the NOWAC study, with particular attention to hormone-dependent cancers and immune microenvironment analysis . Recent publications highlight her expertise in digital pathology and AI-driven tumor classification , including studies on microRNA expression patterns in breast and colon cancer, immune cell score development for NSCLC, and computational approaches to lymphocytic infiltration assessment. Her research directly impacts precision oncology and immunotherapy response prediction . She contributes to teaching as leader of the Musculoskeletal System course at the Medical School, and maintains active participation in scientific knowledge migration projects like the transition to the National Science Archive (NVA). Her ORCID identifier is 0000-0001-8235-6163 .

• Cancer Biomarkers
• Translational Cancer Research
• Digital Pathology
• +۳ مورد دیگر

Norman Van Rhijn is a Wellcome Trust Early Career Fellow at the University of Manchester's Division of Evolution, Infection and Genomics. His research focuses on microbial evolution with specific emphasis on fungal pathogens, particularly Aspergillus fumigatus . He leads work on antimicrobial resistance (AMR), climate change impacts on fungal diseases, and genetic tools for non-model organisms. He holds affiliations with MERman (Microbial Evolution Research Manchster) and the Manchester Fungal Infection Group (MFIG). Education: BSc Biology (Leiden University), MSc Medical Mycology (University of Manchester), PhD in Molecular Biology (University of Manchester). Research highlights include developing CRISPR-based genome editing methodologies, studying fungal adaptation to environmental pressures, and investigating dual-use fungicides. His work contributes to UN Sustainable Development Goals related to health and environmental sustainability. Award: Wellcome Trust Early Career Fellowship. Labs/Teams: PI in the MFIG project, editorial board member for mBio , and active in professional societies including the Microbiology Society and British Society for Medical Mycology.

• Antimicrobial Resistance (AMR)
• Climate Change Impact on Fungal Pathogens
• One Health
• +۳ مورد دیگر

Dr. Andrew J. Woo is a Research Fellow at The University of Western Australia Medical School and the UWA Centre for Medical Research, affiliated with the Harry Perkins Institute of Medical Research. His research focuses on transcriptional gene regulation in stem/progenitor cells of blood and epithelial cancer stem cells. Dr. Woo completed his Bachelor of Science with Honours and PhD in Biochemistry at The University of Western Australia in 2004. He then pursued postdoctoral training under Dr. Alan B. Cantor at Children's Hospital Boston/Dana-Farber Cancer Institute at Harvard Medical School. He returned to Perth in 2012 with a fellowship from the Royal Perth Hospital Medical Research Foundation. Dr. Woo's research interests include understanding transcriptional gene regulatory mechanisms in stem/progenitor cells of blood and epithelial cancer stem cells. With Dr. Peter Leedman at the Harry Perkins Institute of Medical Research, he investigates the role of small non-coding RNA processing complexes in epithelial cancer onset and metastasis. His laboratory employs various techniques including protein-protein interaction identification via proteomics, protein-DNA interaction mapping, transcriptomics, functional genomics, and transgenic mouse models. His recent publications demonstrate a strong focus on cancer research, particularly breast cancer and hepatocellular carcinoma, with significant contributions to understanding transcription factors, oncogenes, and signaling pathways. His work often involves collaboration with other researchers at the Harry Perkins Institute and beyond. Dr. Woo has received the NHMRC project grant near-miss merit award in 2016 and has secured multiple research grants from organizations including Cancer Council of Western Australia and the Medical Research Foundation WA. Dr. Woo has been actively involved in research funding, serving as Chief Investigator on multiple grants since 2012. He also holds an external position as Lecturer and Unit Coordinator at Edith Cowan University from July 2018 to July 2043. His research is conducted within the UWA Centre for Medical Research, which is affiliated with the Harry Perkins Institute of Medical Research, a leading medical research facility in Western Australia.

• Transcriptional gene regulation
• Stem cells and cancer
• Haematopoiesis and blood disorders
• +۵ مورد دیگر

Can Chen is an Assistant Professor in the School of Data Science and Society at the University of North Carolina at Chapel Hill, with adjunct appointments in the Department of Mathematics (College of Arts & Sciences) and the Department of Biostatistics (Gillings School of Global Public Health). He holds core faculty status in the Carolina Health Informatics Program and is affiliated with the Computational Medicine Program and Carolina Center for Interdisciplinary Applied Mathematics. Education: B.S. in Mathematics (UC Irvine, 2016), M.S. in Electrical & Computer Engineering (UMichigan, 2020), Ph.D. in Applied & Interdisciplinary Mathematics (UMichigan, 2021), followed by a postdoc at Brigham and Women’s Hospital/Harvard Medical School (2021–2023). Research interests span control theory, network science, tensor algebra, numerical analysis, machine learning, computational biology, and hypergraph learning. Notable contributions include theoretical frameworks for ecological systems stability, tensor-based dynamical systems, and hypergraph learning applied to genome-scale metabolic networks. Recent work includes a Physics Reports review on ecological stability, a Springer book on tensor algebra, and a Nature Communications paper introducing CHESHIRE for metabolic network analysis. His lab focuses on developing computational tools for systems biology and translational medicine. Key collaborations involve proteogenomic approaches to cancer biomarker discovery, E3 ligase-based targeted therapy, and signal transduction pathways in oncology. He currently oversees research on protein degradation mechanisms, immune-oncology, and systems-driven drug development.

• control theory
• network science
• tensor algebra
• +۷ مورد دیگر

Professor Marcel Dinger is a prominent academic and researcher currently serving as Professor and Head of School for Biotechnology and Biomolecular Sciences at UNSW Sydney. With over 20 years of experience in genomics, he has established himself as a leading figure in both academic and entrepreneurial spheres within the field. He has published 153 papers with over 24,000 citations and maintains an h-index of 61 on Google Scholar. His leadership extends beyond academia as he serves as President of the Australasian Genomics Technologies Association (AGTA) and holds director positions at Pryzm Health and the National Centre for Indigenous Genomics (NCIG). Professor Dinger's research laboratory focuses on establishing new links between phenotype and genotype, particularly examining rare and complex diseases in relation to underexplored regions of the genome including pseudogenes, repetitive elements, non-canonical DNA structures, and noncoding RNAs. His work harnesses population-scale genomic datasets and sophisticated data science methods to bring an objective perspective to understanding how the genome stores information and how it is transacted in biology. His research interests span genomics, non-coding RNA biology, clinical applications of genomic medicine, and the development of computational approaches for analyzing complex genomic data. Analysis of Professor Dinger's recent publications reveals a strong emphasis on non-coding RNA research, particularly long noncoding RNAs and their roles in disease mechanisms. His work spans cancer genomics, neurological disorders, and fundamental genomic mechanisms including DNA secondary structures like i-motifs and G-quadruplexes. His research combines experimental approaches with advanced bioinformatics to address fundamental questions in genomic medicine and has significant translational implications for disease diagnosis and treatment. Highly Cited Researcher in Cross-Field category (2019, 2020, 2021) Fellow of the Faculty of Science (Research), Royal Society of Pathologists of Australasia (2016) NHMRC Career Development Award (2010) Queensland Government Smart Futures Fellowship (2009) Foundation of Research, Science and Technology New Zealand Postdoctoral Fellowship (2005) Professor Dinger has been instrumental in establishing and leading several significant research initiatives including Genome.One, one of the first companies globally to provide clinical whole genome sequencing services, and the Kinghorn Centre for Clinical Genomics at the Garvan Institute of Medical Research. His entrepreneurial experience includes founding four biotechnology and IT startups. He serves on multiple governance boards including the National Centre for Indigenous Genomics, focusing on using genomics to improve health outcomes for Australia's First Peoples. His laboratory at UNSW continues to advance our understanding of genomic regulation and its implications for human health and disease.

• Genomics
• Non-coding RNA research
• Phenotype-genotype relationships
• +۷ مورد دیگر

Sabah Hussain, MD, PhD, is Distinguished James McGill Professor in the Department of Medicine, Faculty of Medicine and Health Sciences at McGill University and Senior Scientist in the Translational Research in Respiratory Diseases Program of the Research Institute of the McGill University Health Centre (RI-MUHC, Glen site). She leads an integrated bench-to-bedside program focused on skeletal-muscle wasting, autophagy, and angiogenesis. Education & Training: MD – University of Baghdad, 1978 PhD (Physiology) – McGill University, 1989 Research Focus: Dr Hussain’s laboratory investigates the molecular machinery governing skeletal-muscle mass in health and disease. Using transgenic models of angiopoietin signaling, sepsis, COPD and mechanical ventilation, her team has dissected how autophagy, mitophagy and proteasomal pathways drive diaphragmatic and locomotor muscle atrophy. A second axis of work explores gene-therapy delivery of angiopoietins to accelerate muscle regeneration after injury or in Duchenne Muscular Dystrophy models. More recently, her group is mapping epigenetic regulators—microRNAs and long non-coding RNAs—that fine-tune these degradative pathways. Scientific Awards & Funding: Distinguished James McGill Professorship CIHR Project Grant – Fall 2024 competition NSERC Discovery Grant – 2024 competition Advising & Mentorship: Dr Hussain mentors graduate students, post-doctoral fellows and clinical research trainees. Sami Sedraoui, a PDF in her group, received the April 2025 Relève-Étoile Jacques-Genest Award from CIHR. Laboratory & Affiliations: Her laboratory is located in the Meakins-Christie Laboratories, RI-MUHC Block E, Glen site (1001 Decarie Blvd, Montréal). The group is embedded within the Centre for Translational Biology and benefits from the RI-MUHC Technology Platforms including Proteomics, Small-Animal Imaging and Molecular Imaging Services.

• Skeletal muscle atrophy and wasting
• Autophagy and mitophagy
• Proteasomal degradation pathways
• +۷ مورد دیگر

John A. Pulikkan, PhD, is an Assistant Professor in the Department of Cell Biology, Neurobiology and Anatomy at the Medical College of Wisconsin. His research focuses on deciphering the interplay between transcription factors and chromatin dynamics in normal and malignant hematopoietic stem cells, with a particular emphasis on acute myeloid leukemia (AML). He leads the Pulikkan Lab, dedicated to identifying novel therapeutic targets for leukemia treatment through genetic, epigenetic, and biochemical approaches in mouse models and human primary leukemic cells. Dr. Pulikkan earned his PhD from Ludwig Maximilian University of Munich, Germany, where his work elucidated mechanisms of C/EBPα in hematopoiesis. His postdoctoral research at the University of Massachusetts Medical School led to the discovery of AI-10-49, a small molecule inhibitor targeting CBFβ-SMMHC in leukemia. This work demonstrated the feasibility of targeting 'undruggable' oncogenic transcription factors, with AI-10-49 now advancing toward clinical development. His research interests span three key areas: (1) transcription factor-chromatin dynamics in hematopoiesis, (2) transcriptional deregulation in AML, and (3) functional roles of non-coding RNAs in leukemia. Notable contributions include insights into MYC chromatin dynamics inhibition and SWI/SNF/PRC axis disruption in cancer. Awards: ASH Scholar Award, Alex's Lemonade Stand Foundation Young Investigator Award, Lauri Strauss Leukemia Foundation Discovery Grant Lab Focus: Translational research bridging basic science and clinical leukemia therapy Key Findings: Role of ADAR2 RNA editing in AML, hijacking of PU.1 antisense promoters by CBF fusions, and N-MYC survival pathways in inv(16) AML

• Chromatin Dynamics
• Hematopoiesis
• Leukemia Biology
• +۳ مورد دیگر

Phillip D. Zamore serves as Chair and Professor of the RNA Therapeutics Institute at the University of Massachusetts Chan Medical School School of Medicine and is an Investigator of the Howard Hughes Medical Institute. He holds the Gretchen Stone Cook Professorship in Biomedical Sciences and leads pioneering research in RNA biology. Dr. Zamore earned his A.B. (1986) and Ph.D. (1992) in Biochemistry and Molecular Biology from Harvard University, followed by postdoctoral training at The Whitehead Institute for Biomedical Research. His research focuses on small RNA silencing pathways including RNA interference (RNAi), microRNA, and PIWI-interacting RNA (piRNA) mechanisms across eukaryotic and prokaryotic systems. Key investigations explore how Argonaute proteins achieve sequence-specific regulation of transcription and translation, with emphasis on piRNA biogenesis in germ cells and bacterial Argonaute functions. Analysis of his recent publications reveals dominant themes in transposon silencing, piRNA pathway evolution, RNA therapeutic development, and molecular mechanisms of gene regulation. His work bridges fundamental biochemistry with clinical applications, particularly in RNA-based therapies for genetic disorders. Notable scientific honors include: Chancellor’s Medal for Excellence in Scholarship (2015) Dean's Award for Research Mentoring (2011) Fellow of the National Academy of Inventors (2014) Election to the American Academy of Arts & Sciences, National Academy of Sciences, and National Academy of Medicine (2023) Dr. Zamore has co-founded multiple biotechnology companies including Alnylam Pharmaceuticals (2002), which developed the FDA-approved RNAi therapeutic ONPATTRO for hereditary transthyretin-mediated amyloidosis, and Voyager Therapeutics (2014). His laboratory has trained dozens of researchers now leading institutions worldwide, with over 150 publications and 119 patents reflecting his translational impact. Current research leverages biochemical and genetic approaches to develop RNA-guided therapies for diseases like Huntington's. The Zamore Laboratory operates within the RNA Therapeutics Institute at UMass Chan Medical School, utilizing advanced genomic, biochemical, and imaging technologies to study small RNA pathways in model organisms including Drosophila, mice, and bacterial systems.

• RNA Interference
• Small RNA Biology
• piRNA Pathways
• +۳ مورد دیگر

Bin Tian, Ph.D., is a Professor in the Department of Biochemistry and Biophysics at The Wistar Institute and serves as Program Co-Leader of the Genome Regulation and Cell Signaling Program at the Ellen and Ronald Caplan Cancer Center. He is also the Director of the Center for Systems & Computational Biology. His research integrates molecular biology, computational genomics, and functional studies to understand RNA processing, particularly alternative polyadenylation (APA), and its roles in cancer and immunity. His educational background includes a B.S. in Biochemistry from East China University of Science and Technology and a Ph.D. in Molecular Biology from Rutgers Biomedical and Health Sciences (formerly UMDNJ). He completed postdoctoral training in bioinformatics and genomics at Johnson & Johnson before establishing his independent lab at Rutgers New Jersey Medical School in 2003, where he became a tenured professor in 2014. He joined The Wistar Institute in 2020. His research focuses on molecular systems biology of RNA, including functional genomics of cleavage and polyadenylation, regulation of gene expression through early transcriptional termination, spatial and temporal control of mRNA metabolism via alternative 3’UTRs, and cleavage and polyadenylation inhibition (CPAi) as a cancer therapeutic strategy. His lab has developed key bioinformatics resources like PolyA_DB, APAlyzer, and MAAPER. His recent publications show a strong trend in dissecting APA mechanisms across physiological and pathological contexts, including cancer, neuronal function, and immune cell differentiation. The work combines high-throughput sequencing, single-cell analysis, and computational modeling to uncover how APA regulates mRNA stability, localization, and function. He mentors a team of postdoctoral fellows, predocotoral trainees, and research assistants, contributing to training the next generation of scientists. His lab is actively pursuing novel therapeutics targeting mRNA 3’ end processing in cancer and immune disorders.

• Molecular Systems Biology
• RNA Processing
• mRNA Metabolism
• +۱۲ مورد دیگر

Jinchuan Xing is a Professor at Rutgers, The State University of New Jersey, where he leads the Xing Lab of Genomics. His research focuses on human genomic variation, mobile DNA elements, evolutionary and population genetics, and their implications for human disease. He integrates computational and experimental methods to study genome-wide variation, with applications in disease gene identification and genomic technology development. His research interests include: Mobile DNA element biology Human demographic history and population diversity Disease gene identification using whole-exome and whole-genome sequencing High-altitude adaptation genetics Transposable element regulation and expression piRNA and small RNA pathways His recent publications highlight a strong trend in reproductive genomics, particularly in identifying genetic risk factors for embryo aneuploidy in IVF patients, using advanced sequencing technologies. Other work spans evolutionary genomics in diverse species (bats, moths, Drosophila), structural variation in neurodevelopmental disorders, and proteogenomic discovery. His lab actively develops and applies bioinformatic tools for variant analysis and gene prioritization. Scientific awards and honors are not explicitly mentioned in the provided text. Jinchuan Xing advises several graduate students, including Nan Wang, Siqi, Ellie Lu, and Tongji Xing. His lab has received significant funding, including an R01 grant from NICHD on aneuploidy risk, a grant from the Center for Human Evolutionary Studies, and a Life Sciences Alliance Pilot Seed Funding grant in collaboration with the Department of Statistics. These grants support research in fertility genomics, disease gene discovery, and genomic tool development. The Xing Lab of Genomics is an active research group conducting interdisciplinary studies combining genomics, bioinformatics, and molecular biology. The lab welcomes new members regularly, including master’s and PhD students, and collaborates across departments. Current projects include understanding the genetic basis of meiosis, fertility, and high-altitude adaptation, as well as developing Markovian gene networks for disease gene discovery.

• Mobile Elements
• Human Genomic Variation
• Evolutionary Genetics
• +۱۴ مورد دیگر